Tavapadon
- Generic Name
- Tavapadon
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16F3N3O3
- CAS Number
- 1643489-24-0
- Unique Ingredient Identifier
- PT4P8MJP8L
- Background
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT02262767
- Locations
- 🇧🇪
Belgium Pfizer Clinical Research Unit, Brussels, Belgium
🇧🇪Pfizer Clinical Research Unit, Brussels, Belgium
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT02224664
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Carolina Phase I Research, LLC, Raleigh, North Carolina, United States
🇺🇸Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY, Boston, Massachusetts, United States
A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01981694
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.